Literature DB >> 2533073

Des-enkephalin-gamma-endorphin (DE gamma E): pharmacokinetics in dogs after intravenous and subcutaneous administration.

J Verhoef1, H M van den Wildenberg.   

Abstract

After intravenous dosing in dogs [3H-Lys9]-DE gamma E (Org 5878) was very rapidly eliminated from the circulation. Disappearance of the neuropeptide from blood followed a biphasic decay with half-lives of 0.6 +/- 0.1 min (+/- S.D.; alpha-phase) and 2.4 +/- 1.0 min (beta-phase). The central volume of distribution ranged between 0.05 and 0.23 l.kg-1. The mean blood clearance rate amounted to 0.15 l.min-1.kg-1, which is indicative of extensive hepatic and extrahepatic metabolism of DE gamma E. In contrast to intravenous dosing, subcutaneous injection of [3H]-DE gamma E in dogs resulted in low but relatively long-lasting peptide levels in blood. Peak values were found at 5-10 min, whereafter they declined to the limit of detection at 1.5-2 h. The bioavailability of DE gamma E for this route of administration was shown to be 20-23%.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2533073     DOI: 10.1007/BF03190103

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  12 in total

1.  Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

Authors:  C C Peck; S L Beal; L B Sheiner; A I Nichols
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

2.  Selective attenuation of passive avoidance behaviour by microinjection of beta-LPH62-77 and beta-LPH66-77 into the nucleus accumbens in rats.

Authors:  G L Kovács; G Telegdy; D De Wied
Journal:  Neuropharmacology       Date:  1982-05       Impact factor: 5.250

3.  Blood-cerebrospinal fluid barrier to arginine-vasopressin, desmopressin and desglycinamide arginine-vasopressin in the dog.

Authors:  V T Ang; J S Jenkins
Journal:  J Endocrinol       Date:  1982-06       Impact factor: 4.286

4.  Neuroleptic-like activity of peptides related to [DesTyr1] gamma-endorphin: structure activity studies.

Authors:  D de Wied; J M van Ree; H M Greven
Journal:  Life Sci       Date:  1980-05-12       Impact factor: 5.037

5.  [3H]9-desglycinamide,8-arginine vasopressin: metabolism and in-vivo fate.

Authors:  J Verhoef; H M van den Wildenberg; J W van Nispen
Journal:  J Endocrinol       Date:  1986-09       Impact factor: 4.286

6.  Antipsychotic properties of Des-enkephalin-gamma-endorphin in treatment of schizophrenic patients.

Authors:  W M Verhoeven; J M van Ree; A Heezius-van Bentum; D de Wied; H M van Praag
Journal:  Arch Gen Psychiatry       Date:  1982-06

7.  Des-enkephalin-gamma-endorphin (DE gamma E): biotransformation in rat, dog and human plasma.

Authors:  J Coos Verhoef; H M Van den Wildenberg; J W Van Nispen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Oct-Dec       Impact factor: 2.441

8.  Absorption of alpha-MSH from subcutaneous and intraperitoneal sites in the rat.

Authors:  A Wright; J F Wilson
Journal:  Peptides       Date:  1983 Jan-Feb       Impact factor: 3.750

9.  Des-enkephalin-gamma-endorphin: bioavailability in rats following the subcutaneous and intramuscular route of administration.

Authors:  J C Verhoef; H M van den Wildenberg
Journal:  Regul Pept       Date:  1986-04

10.  Des-Tyr1-gamma-endorphin (DT gamma E) and des-enkephalin-gamma-endorphin (DE gamma E): plasma profile and brain uptake after systemic administration in the rat.

Authors:  J C Verhoef; H Scholtens; E G Vergeer; A Witter
Journal:  Peptides       Date:  1985 May-Jun       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.